

References

I-181

1. Clinical Pharmacology™ Compendium 2021. Tampa FL: Gold Standard, Inc. Pralatrexate.
2. National Comprehensive Cancer Network (NCCN). Pralatrexate. NCCN Drugs and Biologics Compendium®. 2021.
3. Folutyn (pralatrexate), for injection [package insert]. Allos Therapeutics, Inc.. Westminster, CO. Revised 09/2020.
4. Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial. *British Journal of Haematology*. 2016;172(4):535-544.
5. Duvic M, Kim YH, Zinzani PL, et al. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. *Clin Cancer Res*. 2017;23(14):3552-3556.
6. Amengual JE, Lichtenstein R, Lue J, et.al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. *Blood*. 2018 Jan 25;131(4):397-407.
7. Kelly KR, Gabrail N, Weitman S, et.al. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. *Cancer Chemother Pharmacol*. 2016 Nov;78(5):929-939.